SynthesisFrontiers in immunology2026
IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IL-17 pathway inhibitors are established treatments for active psoriatic arthritis (PsA), but comparative evidence within this therapeutic class remains limited. We compared the efficacy, safety, treatment rankings, and certainty of evidence for established and emerging IL-17 pathway inhibitors in adults with active PsA. Methods: We conducted a PRISMA-compliant systematic review and network meta-analysis. MEDLINE via PubMed, Embase via Ovid, CENTRAL, ClinicalTrials.gov, and the EU Clinical Trials Register were searched from January 1, 2010, to January 18, 2026. Eligible studies were phase 2 or phase 3 randomized controlled trials in adults with PsA. The primary outcome was ACR50 at Weeks 12-16. Secondary outcomes included ACR20, ACR70, PASI90, minimal disease activity, HAQ-DI, safety outcomes, Week-24 outcomes, and descriptive Week-52 outcomes. Frequentist random-effects network meta-analysis was performed; certainty was assessed using CINeMA. Results: Sixteen RCTs were included. The primary ACR50 network comprised eight RCTs and ten treatment nodes. All active treatments were superior to placebo for ACR50 at Weeks 12-16, with negligible heterogeneity (τ² = 0; I² = 0%) and no important incoherence. Ixekizumab Q2W had the highest ACR50 P-score, followed by bimekizumab 160 mg with loading and ixekizumab Q4W; however, active-treatment confidence intervals overlapped. Secondary outcomes showed consistent improvements in joint, skin, multidomain, and functional endpoints. Sonelokimab and izokibep showed favorable exploratory estimates but very low certainty. Serious adverse events and discontinuations were not clearly increased versus placebo. Bimekizumab showed a modest increase in infection risk and a higher Candida signal; IBD events were rare. Conclusion: IL-17 pathway inhibitors are effective short-term treatments for active PsA. Rankings suggest potential within-class differences, but indirect comparisons and overlapping confidence intervals limit definitive superiority claims. Candida risk and patient-specific factors should inform individualized treatment selection. The protocol was registered in PROSPERO (CRD420251156756). Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251156756, identifier CRD420251156756.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.